FDA rejects Coherus's biosimilar for Amgen's Neulasta

(Reuters) - Coherus BioSciences Inc said on Monday the U.S. Food and Drug Administration denied the approval of its biosimilar for Amgen Inc's Neulasta, which fights infections in cancer patients.